Nebivolol in chronic coronary syndrome treatment – β-blocker with unique properties

Bartosz Krzowski; Marcin Grabowski

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

2/2021
vol. 7

Send email

Copy url:

abstract:

Nebivolol in chronic coronary syndrome treatment – β-blocker with unique properties

Bartosz Krzowski

¹

,

Marcin Grabowski

¹

I Katedra i Klinika Kardiologii Warszawskiego Uniwersytetu Medycznego, Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie

Online publish date: 2021/05/22

View full text Get citation

Several methods of chronic coronary syndrome treatment have been described, ranging from lifestyle modifications to pharmacotherapy and invasive procedures. Adjusting the right drug to a specific patient might be a challenge, mainly due to the number of molecules available on the market. One of the main groups of drugs used on a daily basis by internal medicine physicians and cardiologists are β-blockers, which have proven their effectiveness in many clinical trials. Their impact on the improvement of prognosis and quality of life has been proven. Nebivolol is a prominent representative of this group. Its high selectivity for β receptors and its pleiotropic effect of action have been the subject of many studies presenting the clinical benefits for patients. The presented manuscript concerns the most important findings on the use of nebivolol in patients with chronic coronary syndromes.

keywords:

Nebivolol in chronic coronary syndrome treatment – β-blocker with unique properties

Bartosz Krzowski 1 , Marcin Grabowski 1

nebivolol, chronic coronary syndromes, MINOCA

Bartosz Krzowski

¹

,

Marcin Grabowski

¹